These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32281569)

  • 21. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.
    Evans DB; George B; Tsai S
    Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?
    Wolff RA
    Surg Clin North Am; 2018 Feb; 98(1):95-111. PubMed ID: 29191281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy].
    Arkosy P; Sasi SL; Enyedi A; Szántó J; András C; Sápy P
    Magy Seb; 2005 Feb; 58(1):29-33. PubMed ID: 16018598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal.
    Eshmuminov D; Aminjonov B; Palm RF; Lehmann K
    Ann Surg Oncol; 2023 Jul; 30(7):4429-4430. PubMed ID: 37074518
    [No Abstract]   [Full Text] [Related]  

  • 25. Perioperative management of pancreatic cancer.
    Heinemann V; Boeck S
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii273-8. PubMed ID: 18790965
    [No Abstract]   [Full Text] [Related]  

  • 26. [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].
    Bai XL; Li X; Liang TB
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):486-489. PubMed ID: 32610415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant and neoadjuvant approaches in pancreatic cancer.
    Conroy T; Lambert A; Ducreux M
    Curr Opin Oncol; 2023 Jul; 35(4):326-333. PubMed ID: 37222189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer.
    Gleeson EM; Leigh N; Golas BJ; Magge D; Sarpel U; Hiotis SP; Labow DM; Pintova S; Cohen NA
    Pancreas; 2021 Sep; 50(8):1163-1168. PubMed ID: 34714279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
    D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
    Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progress in neoadjuvant and transformation therapy of pancreatic cancer].
    Hu DD; Dai MH
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):69-72. PubMed ID: 28056259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
    Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
    Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer.
    Søreide K
    Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):205-206. PubMed ID: 35221247
    [No Abstract]   [Full Text] [Related]  

  • 34. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.
    Blair AB; Sorber R; Rozich NS; Burkhart RA
    Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neoadjuvant and adjuvant treatment of pancreatic cancer].
    Springfeld C; Hackert T; Jäger D; Büchler MW; Neoptolemos JP
    Chirurg; 2020 Aug; 91(8):636-641. PubMed ID: 32300820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A Case of Pathological Complete Response after Neoadjuvant Therapy for Resectable Pancreatic Cancer].
    Shimojima Y; Nomura T; Takano K; Nakayasu Y; Kono T; Kuhara K; Usui T; Asaka S; Yokomizo H; Shimakawa T; Ohigashi S; Shiozawa S
    Gan To Kagaku Ryoho; 2022 Dec; 49(13):1662-1664. PubMed ID: 36733168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of adjuvant therapy in the management of pancreatic cancer.
    Laheru D; Yeo CJ
    Adv Surg; 2005; 39():223-44. PubMed ID: 16250554
    [No Abstract]   [Full Text] [Related]  

  • 40. Active Systemic Treatment of Pancreatic Cancer.
    Tempero M
    J Natl Compr Canc Netw; 2017 May; 15(5S):723-725. PubMed ID: 28515255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.